Literature DB >> 17180509

Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.

Satomi Yakushiji1, Masashi Ando, Kan Yonemori, Tsutomu Kohno, Chikako Shimizu, Noriyuki Katsumata, Yasuhiro Fujiwara.   

Abstract

BACKGROUND: Cancer of unknown primary (CUP) is not a rare clinical entity, accounting for 3%-5% of all solid malignancies.
METHODS: We retrospectively reviewed 86 (38 male/48 female) patients with a diagnosis of CUP (exclusive of female patients with adenocarcinoma involving the axillary lymph nodes alone and patients with squamous cell carcinoma of the cervical lymph nodes) who were referred to the National Cancer Center Hospital between April 1996 and October 2002.
RESULTS: The median interval between the first visit to a local community hospital and referral to our hospital was 1 month (range, 1 to 45 months). The histological diagnosis was adenocarcinoma in 61 patients (71%), poorly differentiated carcinoma in 18 patients (21%), and squamous cell carcinoma in 4 patients (5%). Twenty-three female patients had peritoneal carcinomatosis of adenocarcinoma. Seventy-eight patients (91%) received platinum-containing chemotherapy. Sixty-one of the 86 patients (71%) were categorized as a subgroup of CUP without a specific therapy, and 55 of these 61 patients (90%) received platinum-containing regimens. The median survivals of all 86 patients and the 61 patients in the subgroup without a specific therapy in this series were 13 months and 11 months, respectively.
CONCLUSION: In this series, the survival of the patients in the CUP subgroup without a specific therapy did not seem worse than that in previous reports. Empirical chemotherapy with platinum-containing regimens may benefit some CUP patients in a subgroup without a specific chemotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 17180509     DOI: 10.1007/s10147-006-0599-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  25 in total

1.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

2.  Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.

Authors:  E Voog; Y Merrouche; V Trillet-Lenoir; C Lasset; P Y Peaud; P Rebattu; S Negrier
Journal:  Am J Clin Oncol       Date:  2000-12       Impact factor: 2.339

3.  Diagnostic persistence in working up metastatic cancer with an unknown primary site.

Authors:  R J Steckel; A R Kagan
Journal:  Radiology       Date:  1980-02       Impact factor: 11.105

4.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.

Authors:  J D Hainsworth; D H Johnson; F A Greco
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

5.  Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.

Authors:  Hirofumi Mukai; Toru Watanabe; Masashi Ando; Noriyuki Katsumata
Journal:  Int J Clin Oncol       Date:  2003-02       Impact factor: 3.402

6.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

Authors:  Stéphane Culine; Alain Lortholary; Jean-Jacques Voigt; Roland Bugat; Christine Théodore; Frank Priou; Marie-Christine Kaminsky; Thierry Lesimple; Xavier Pivot; Bruno Coudert; Jean-Yves Douillard; Yacine Merrouche; Jelila Allouache; Alain Goupil; Sylvie Négrier; Juliette Viala; Peter Petrow; Jeannine Bouzy; Agnès Laplanche; Karim Fizazi
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

7.  Axillary lymph node metastasis from an occult breast cancer.

Authors:  J Patel; T Nemoto; D Rosner; T L Dao; J W Pickren
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

8.  Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.

Authors:  M N Raber; J Faintuch; J L Abbruzzese; C Sumrall; P Frost
Journal:  Ann Oncol       Date:  1991-07       Impact factor: 32.976

9.  Multi-platform, multi-site, microarray-based human tumor classification.

Authors:  Greg Bloom; Ivana V Yang; David Boulware; Ka Yin Kwong; Domenico Coppola; Steven Eschrich; John Quackenbush; Timothy J Yeatman
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 10.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  4 in total

1.  Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East.

Authors:  Nobuaki Matsubara; Hirofumi Mukai; Shunji Nagai; Kuniaki Itoh
Journal:  Int J Clin Oncol       Date:  2010-08-11       Impact factor: 3.402

2.  Ampullary cancer detected upon re-examination in a patient initially diagnosed as cancer of unknown primary.

Authors:  Yasuharu Kawamoto; Kenji Ikezawa; Shinichiro Hasegawa; Hiroshi Wada; Toshihiro Kudo; Shigenori Nagata; Kazuyoshi Ohkawa
Journal:  JGH Open       Date:  2022-02-08

3.  Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.

Authors:  K Yonemori; M Ando; M Yunokawa; T Hirata; T Kouno; C Shimizu; K Tamura; N Katsumata; A Hirakawa; K Matsumoto; Y Yamanaka; H Arioka; Y Fujiwara
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

4.  Limitations and usefulness of biopsy techniques for the diagnosis of metastatic bone and soft tissue tumors.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Naohiro Oka; Masao Akagi
Journal:  Ann Med Surg (Lond)       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.